Ivelin Georgiev

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants. Read More

A collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine. The group used multiple single-cell technologies, unbiased machine learning and traditional immunological approaches to track cellular and antibody responses in samples collected over time from a cohort of healthy participants. Read More

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. Read More

An innovative Vanderbilt program that brings together scientists and artists with the shared goal of scientific communication is set to expand with support from a three-year grant from the Burroughs Wellcome Fund. Read More

Ten outstanding faculty members from across the university have been selected for the 2020 cohort of Chancellor Faculty Fellows. This group is composed of highly accomplished, recently tenured faculty from a wide variety of disciplines and areas of expertise. Read More

Antibody discovery and vaccine development research may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues. Read More

Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus. Read More